Hormone Replacement Therapy and Menopause: What the Evidence Actually Says and How to Access Care
Few topics in women's health have generated as much confusion as hormone replacement therapy. The treatment that was once the standard of care for menopause symptoms fell sharply out of favour in the early 2000s following publication of a major study that appeared to associate it with elevated risks of breast cancer and cardiovascular events. In the years since, that study has been substantially reanalysed and its conclusions significantly revised, but the fear it generated did not retreat at the same pace. Many women who could benefit from hormone therapy continue to avoid it based on information that is now two decades out of date.
Understanding what the evidence actually shows, what treatment involves, and how to access care through modern channels is a more useful starting point than the accumulated anxiety around a single study.
What the Research Actually Shows Now
The Women's Health Initiative trial, published in 2002, studied women who began combined oestrogen and progestogen therapy at an average age of 63, more than a decade past average menopause age. The results showed a small but statistically significant increase in breast cancer risk in this population, as well as increased cardiovascular events. The study was widely reported as demonstrating that HRT was broadly dangerous for postmenopausal women.
Subsequent reanalysis of the data, along with a series of later studies, revealed a more nuanced picture. The risks observed were primarily associated with older women who began hormone therapy well past menopause and for whom the cardiovascular risk profile was already elevated. For women who begin hormone therapy within ten years of menopause onset and before age 60, the evidence consistently shows a more favourable risk profile. The "timing hypothesis" in menopause research suggests that the cardiovascular effects of oestrogen differ depending on whether oestrogen is reintroduced during a window relatively close to menopause, or much later when arterial health has already changed.
The current clinical guidance from the Menopause Society and other major bodies reflects this evolution: for healthy women under 60 within ten years of menopause, the benefits of hormone therapy for quality of life generally outweigh the risks, and the risks themselves are lower than the post-WHI interpretation suggested.
What Hormone Therapy Involves
Hormone replacement therapy typically involves oestrogen, and for women who have not had a hysterectomy, a progestogen to protect the uterine lining from the stimulating effects of oestrogen alone. The combination and delivery method are tailored to the individual based on their symptom profile, medical history, and risk factors.
Oestrogen is available in several delivery formats, including oral tablets, transdermal patches, gels, and vaginal preparations. Transdermal delivery, which delivers oestrogen through the skin directly into the bloodstream, is associated with a lower risk of blood clots than oral forms because it bypasses first-pass liver metabolism. For women with specific concerns about clot risk, transdermal preparations are generally the preferred starting point.
Progestogen is available as synthetic progestogens (progestins) or as body-identical progesterone derived from plants. Research suggests that micronised progesterone, the body-identical form, may have a more favourable safety profile with respect to breast cancer risk compared to synthetic progestins, and it is often preferred in current prescribing.
The decision about which specific formulation and dose to use is one that involves a clinician reviewing a woman's full health picture. The goal is the lowest effective dose for an adequate period, with regular review as needs and health status evolve.
Symptoms Hormone Therapy Addresses
The primary indication for HRT is the relief of vasomotor symptoms: hot flashes and night sweats. These are the most common and often the most disruptive menopause symptoms, affecting a majority of women to varying degrees. Hormone therapy is the most consistently effective treatment for vasomotor symptoms, reducing their frequency and severity significantly in most women who use it.
Beyond vasomotor symptoms, hormone therapy addresses genitourinary symptoms including vaginal dryness, discomfort during sex, and urinary urgency that arise from declining oestrogen levels and do not resolve without intervention. It supports bone density and reduces fracture risk. For many women, it also improves sleep quality, mood stability, and cognitive clarity, though these effects are more variable and context-dependent than the relief of vasomotor and genitourinary symptoms.
Accessing Hormone Therapy Through Online Care
The option of accessing hormone replacement therapy online through a telehealth platform has made initiating menopause care significantly more accessible for women who previously faced barriers of distance, waiting time, or limited access to providers familiar with current prescribing guidance.
The process involves completing a detailed health intake that covers symptom history, medical history, current medications, and relevant family history. A licensed provider reviews the intake and, where the clinical picture supports it, develops a personalised treatment plan. For many women, this can include a prescription for appropriate hormone therapy that is delivered to their home. Follow-up through the platform allows the treatment plan to be adjusted as the clinical picture evolves.
The ability to have a thorough conversation about menopause symptoms and treatment options without scheduling a specialist appointment or waiting for a referral to be processed removes barriers that previously prevented many women from receiving the care they need during a life stage when the impact of undertreated symptoms can be substantial.
Not every woman will be a candidate for hormone therapy, and a responsible online platform will identify clinical situations where in-person assessment, additional testing, or specialist care is required. The value of online access is that it brings more women into an appropriate initial care relationship rather than leaving them to manage symptoms without clinical support.
Frequently Asked Questions
Who is hormone replacement therapy suitable for?
HRT is generally considered most suitable for women experiencing moderate to severe menopause symptoms who are under 60 or within ten years of menopause onset, and who do not have specific contraindications such as certain hormone-sensitive cancers or a history of blood clots. Individual assessment with a knowledgeable provider determines suitability for each person.
How quickly does hormone therapy begin to work?
Vasomotor symptom relief typically begins within a few weeks of starting therapy, with more significant improvement developing over the first two to three months. Genitourinary symptoms may take longer to improve fully, particularly if they have been present for some time before treatment begins.
Does hormone therapy cause weight gain?
HRT does not cause weight gain. Menopause itself is associated with changes in body composition and fat distribution due to declining oestrogen levels, but research has not found that hormone therapy increases weight beyond what would occur in untreated menopause. Some women report that HRT improves their ability to manage weight by improving sleep and reducing fatigue.
How long can hormone therapy be taken?
There is no fixed maximum duration. Current guidance supports using HRT for as long as a woman benefits from it and the benefits continue to outweigh any risks, with regular clinical review. The practice of routinely stopping HRT after five years is not supported by current evidence for most women.
What is the difference between synthetic hormones and body-identical hormones?
Body-identical hormones have a molecular structure identical to the hormones produced by the body. Synthetic hormones, such as the progestins used in many older HRT formulations, have a different molecular structure that affects how they interact with hormone receptors. Research suggests that body-identical progesterone may have a more favourable safety profile than synthetic progestins. A prescribing provider can advise on the available formulations and their relative profiles based on your individual situation.